LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

Search

Puma Biotechnology Inc

Closed

SectorHealthcare

3.62 1.69

Overview

Share price change

24h

Current

Min

3.49

Max

3.68

Key metrics

By Trading Economics

Income

-16M

3M

Sales

-13M

46M

P/E

Sector Avg

4.59

54.533

EPS

0.1

Profit margin

6.464

Employees

172

EBITDA

-14M

4M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+20.95% upside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

18M

178M

Previous open

1.93

Previous close

3.62

News Sentiment

By Acuity

26%

74%

62 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

20 maj 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

PNC to Buy Private-Equity Agent Aqueduct Capital

20 maj 2025, 20:50 UTC

Earnings

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 maj 2025, 23:48 UTC

Acquisitions, Mergers, Takeovers

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 maj 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 maj 2025, 23:39 UTC

Market Talk

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 maj 2025, 23:08 UTC

Market Talk

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 maj 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 maj 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 maj 2025, 22:20 UTC

Top News

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 maj 2025, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 maj 2025, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 maj 2025, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 maj 2025, 21:44 UTC

Earnings

James Hardie Industries 4Q Adj EPS 36c >JHX

20 maj 2025, 21:44 UTC

Earnings

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 maj 2025, 21:44 UTC

Earnings

James Hardie Industries 4Q EPS 10c >JHX

20 maj 2025, 21:44 UTC

Earnings

James Hardie Industries 4Q Sales $972M >JHX

20 maj 2025, 20:52 UTC

Top News

Elon Musk to Cut Back Political Spending -- 3rd Update

20 maj 2025, 20:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 maj 2025, 20:52 UTC

Market Talk

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 maj 2025, 20:30 UTC

Acquisitions, Mergers, Takeovers

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 maj 2025, 20:28 UTC

Acquisitions, Mergers, Takeovers

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 maj 2025, 20:23 UTC

Acquisitions, Mergers, Takeovers

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 maj 2025, 20:22 UTC

Earnings

XP 1Q Adj EPS BRL2.29 >XP

20 maj 2025, 20:22 UTC

Earnings

XP 1Q Rev BRL4.345B >XP

20 maj 2025, 20:21 UTC

Acquisitions, Mergers, Takeovers

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 maj 2025, 20:20 UTC

Top News

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 maj 2025, 20:19 UTC

Acquisitions, Mergers, Takeovers

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 maj 2025, 20:11 UTC

Top News

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 maj 2025, 20:09 UTC

Earnings

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

20 maj 2025, 20:08 UTC

Earnings

Palo Alto Networks Sees FY25 Adj EPS $3.26-Adj EPS $3.28 >PANW

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

20.95% upside

12 Months Forecast

Average 4.33 USD  20.95%

High 7 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

3 ratings

1

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

62 / 382 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.